Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer

The purpose of this study was to determine the change in overall survival (OS) for patients with de novo metastatic breast cancer (dnMBC) over time. We conducted a retrospective cohort 1981 dnMBC diagnosed between January 1995 and December 2017 at University Texas MD Anderson Cancer Center. OS measured from date diagnosis dnMBC. compared during different time periods: 5-year periods defined according when key agents were approved clinical use. median 3.4 years. 5- 10-year rates improved across both types periods. A subgroup analysis showed that significantly estrogen-receptor-positive/HER2-positive (ER+/HER2+) subtype exhibited tendency toward improvement ER-negative (ER?)/HER2+ subtype. In addition, longer non-inflammatory (p = 0.02) ER+ disease, progesterone-receptor-positive HER2+ lower nuclear grade, locoregional therapy, metastasis single organ (all p < 0.0001). These findings 5 10 years after significant improvements ER+/HER2+ ER?/HER2+ suggest contribution HER2-targeted therapy survival.